Our Team

Dr. T. Nathan Yoganathan
President and Chief Scientific Officer


Dr. T. Nathan Yoganathan is currently the President and Chief Scientific Officer of KalGene Pharmaceuticals. Dr. Yoganathan is a university and industrial research scientist, turned entrepreneur who became an experienced CEO, having successfully launched a public biotechnology company. He has over twenty-five years of experience in scientific research in cell signaling and gene expression technology, and has published several articles, and is an inventor of many patents.

Dr. Yoganathan is the recipient of numerous awards, including ones from the Natural Sciences and Engineering Research Council of Canada, and the Thyroid Foundation of Canada. He serves on a number of advisory boards for both government and industry, including the CIHR Strategic Training Program in the Bioinformatics Advisory Board, BIOTECanada’s Emerging Companies Advisory Board, and the Ontario Research Fund Advisory Board. He was elected as a Fellow of the Royal Society of Biology.

Dr. Yoganathan was a faculty member of the Department of Medicine at the University of Toronto, and was affiliated with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. He holds a B.Sc. (Honours) from the University of North London, a M.Sc. from the University of Sussex, and a Ph.D. from the University of Oslo.

Dr. John W. Gillard
Vice President Product Development


Dr. John Gillard, is KalGene's VP, Product Development. Dr. Gillard was a founder and Chief Scientific Officer (CSO) of Aegera Therapeutics Inc., which developed a pioneering oncology technology from discovery through to an out-licensed clinical product. He helped build the 55-person biotechnology company and attract more than $65M in investment over 12 years. He formerly worked at Merck and Biochem Pharma and has had extensive success managing academic-industry collaborative ventures, large pharma licensing deals and post-deal collaborations.

Dr. Patrick Tremblay
Senior Scientific Advisor


Patrick Tremblay is a biopharmaceutical and investment executive with broad expertise in R&D and business development. 

Patrick has worked with Pappas Ventures, a U.S.-based venture capital firm that guided the development of more than 50 life science companies in therapeutics, diagnostics, medical devices and personalized medicine. He held positions as Vice-president of R&D at BioAxone and as Director of Pharmacology at Neurochem where he developed neuroprotective and neuroregenerative drugs for Alzheimer’s disease and spinal cord injury. He was also Assistant Professor in Neurology at the University of California in San Francisco where he worked on neurodegenerative diseases induced by prions and was part of the Nobel Laureate Team of Stanley Prusiner, Medicine and Physiology (1997).

Patrick has been involved in many innovative life science initiatives. He is one of the co-founders of the Personalized Medicine Partnership for Cancer and was intimately involved in the creation and financing of the new Neomed Institute. In recent years, he has held numerous advisory positions with diverse organizations such as the Campus des Technologies de la Santé, Quebec Consortium for Drug Discovery, Centre of Excellence for Commercialization and Research of the Montreal Neurological Institute and at Pharmacology Institute of Sherbrooke University. He is presently a member of the Board of Directors of Univalor.

Patrick holds a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Molecular Biology from the University of Montreal. He has also completed post-doctoral studies at the Max Planck Institute for Biophysical Chemistry in Germany.

Scientific Advisory Board

Dr. Dave Morgan


Dr. Dave Morgan is Chief Executive Officer/Director of the USF Health Byrd Alzheimer Institute. He is also Professor of Molecular Pharmacology and Physiology and Director of Neuroscience Research for the College of Medicine at the University of South Florida.

Dr. Morgan’s research interests are brain function and aging with a focus on drugs to treat Alzheimer’s dementia. His doctoral research investigated the neurochemistry of memory and his postdoctoral studies addressed aging-related changes in rodent and human brains.

Morgan became a faculty member at the University of Southern California in 1986 where his research projects focused on astrocytes and microglia in the aged brain, including Alzheimer's tissues.
After moving to South Florida in 1992, Dr. Morgan participated in the development of a transgenic mouse model of Alzheimer's disease (APP+PS1). He has developed methods to measure the damage occurring in the brains of the study mice and how it causes memory deficits.

His work focuses largely on the neuro-immune interactions associated with the Alzheimer phenotype. He is presently testing amyloid dissolving agents, amyloid immunotherapy and gene therapy to treat the Alzheimer-like changes in transgenic mouse models of the disease. This work is supported by multiple grants from the NIH, private foundations and contracts from industrial partners.

An antibody against the amyloid peptide that was characterized in his laboratory has entered clinical testing in AD patients. Morgan regularly sits on review panels for NIH and other agencies evaluating grants to develop new drugs to treat Alzheimer's and other neurodegenerative disorders.

In addition to his research activities, Morgan has consulted with pharmaceutical and biotechnology companies regarding the development of therapeutics for Alzheimer's disease, and advised capital investment organizations regarding the most promising therapeutic approaches to curing Alzheimer’s disease.